Q4 2020

Source filing unavailable

Q4 2020 · —

derived · Computed from the longer spans the company filed.

Revenue—

Net Income

-$1.54M

derivedno prior Q4 2019 on file

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Cash Flowderived-$1,717,691—

Free Cash Flowderived-$1,717,691—

Same quarter

no prior Q4 2019 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

MiNK Therapeutics, Inc. · CIK 1840229 · Engraved from SEC EDGAR